Introduction

The HLA Equivalency Table Update Sub Committee met via teleconference on 12/04/2019 to discuss the following agenda items:

1. HLA Equivalency Table Review/Update

The following is a summary of the Sub Committee’s discussions.

1. HLA Equivalency Table Review/Update

Discussion:

The Subcommittee is tasked with conducting the annual table review, per OPTN Policy. They have been researching for additions, deletions, corrections. The Subcommittee has also been addressing the use of an expedited pathway for approval in the future, as well as the use of epitopes.

- Lunz – created summary document for greater clarity on recommended additions, deletions, and pertinent for the group.
  - Table 4-3 –
    - Should B62 include B15:24 as an equivalency?
      - Group feels this should not be added to the table b/c 15:24 does not consistently react as an equivalent.
    - Add B83 as an antigen? Should this be B83 or 83:01?
      - List at the antigen level?
        - No, B83 is not consistent with the WHO nomenclature
      - What of the nomenclature?
        - Call it 83:01
    - B27 include B*27:08 as an equivalent?
      - Group feels this should not be added to the table b/c 27:08 as they are not equivalent.
  - Table 4-4 –
    - Add DR103 to DR 01:03?
      - Yes
    - Add 03:03 to DR 3
      - Add as this was an omission
    - Add the DR changes that were approved by the Board on 12/3/2019.
    - Schiller – she agrees with the approach to gaps between the antigen and UA tables. Why does the OPTN include options for the low resolution test kits rather than the common/well documented (CWD) alleles?
Lunz – theorizes the OPTN is playing catch-up based on test kit capabilities and what people are reporting as alleles or antibodies. There needs to be a balance of listing the pertinent antigens/alleles that can be identified and the CWD. He acknowledges the need for parity between the reference tables and programming, as well as the administrative process for updates in the future. This update is a step in moving to a direction of a smarter approach to updates in the future.

- Table 4-5 – no changes recommended
- Table 4-6 –
  - Remove 50:02 as equivalent to donor 50
    - Everyone agreed.
  - Remove 21 as an equivalent to 50:01
    - Everyone agreed.
  - Remove 12 as equivalent to 50:02
    - Everyone agreed.
  - Is 83 a Bw4 or Bw6, or none?
    - Group favored leaving 83 alone and not adding to Bw4 or Bw6
- Table 4-7-
  - Add 06:02 to 6
  - Remove 03:05 as donor equivalent to 10
    - Jenny – she favored discussing this; C*03:05 doesn’t have a serological equivalent to C10 based on the HLA dictionary. Group supported removing this from the draft. She mentioned a couple typos 07:06 and 07:18 are equivalent to C*07 and 16:04 with 16:02.
- Table 4-8 –
  - Remove 01:03 as a donor equivalent antigen as 1
    - Everyone agreed.
  - Add 103 as a donor equivalent antigen to 01:03
    - Everyone agreed.
  - Add 13:05 as a donor equivalent antigen to 6
    - Everyone agreed.
  - Add 103 as a candidate unacceptable DR locus antigen with 103 and 01:03 as donor equivalent antigens
    - Everyone agreed.
- Table 4-9 – no changes recommended
- Table 4-10 – no changes recommended
- Table 4-11 – no changes recommended
- Table 4-12 – no changes recommended
- Table 4-13 –
  - Remove DQB1 as a donor equivalent antigen to all donor equivalent antigens
    - Most labs would revert to low resolution testing for DQB5 or DQB6. This will reduce discrepancies in reporting. Molecular typing for donors is required. The group supports.
- Table 4-14 –
  - 04:01 needed to include add his addition.
- Table 4-15 –
Lunz – he explained the purpose of this table to the Subcommittee. Should we have two tables for DPB1? By not merging the two?
  • Schiller – favors one comprehensive table for simplicity. Two tables is more complex.
  • Lunz – would favor 4-14 only showing equivalences, and 4-15 would include everything for DPB1. Thus 4-15 would need to be amended to include everything in 4-14.
  • Schiller – need to tweak policy language around 4-14 and 4-15 “HLA” → “HLA typing”
  ○ Table 4-16 –
    • Allen – suggests we list the epitope, but also add the first amino acid to make it easier for individuals to use the tables AAE → 55AAE
    • John agrees. Benefit to add a note for clarity.

Does the Subcommittee recommend moving forward to the Committee?

Yes

Next steps:
The Subcommittee is continuing its review of the tables in preparation for presentation to the full Histocompatibility Committee on December 10. Following approval by the Committee, the proposal will be vetted for public comment January 22-March 24, 2020.

Upcoming Meeting
  • n/a